What is Loprinone used for?

Loprinone is indicated for Acute heart failure.

What development phase is Loprinone in?

Loprinone is FDA-approved (marketed).

What is the generic name of Loprinone?

OLPRINONE is the generic (nonproprietary) name of Loprinone.

Last reviewed 2026-04-20 · How we verify

Loprinone (OLPRINONE)

FDA-approved active Small molecule Quality 24/100

Loprinone, marketed as Olprinone, is a phosphodiesterase 3 inhibitor indicated for acute heart failure, currently holding a niche position in the market. Its key strength lies in its mechanism of action, which allows the heart to function more efficiently, potentially offering a therapeutic advantage over older off-patent competitors like choline theophyllinate and dipyridamole. The primary risk to Loprinone's market position is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	OLPRINONE
Drug class	olprinone
Target	Phosphodiesterase 3
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Approved indications

Acute heart failure

Common side effects

No common side effects on file.

Key clinical trials

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Loprinone CI brief — competitive landscape report
Loprinone updates RSS · CI watch RSS